Azitra (AZTR) Cash from Investing Activities (2022 - 2026)
Azitra's (AZTR) quarterly Cash from Investing Activities came in at -$37139.0 in Q1 2026, down 71.26% YoY from -$129214.9 in Q1 2025, and up 55.71% on a QoQ basis from -$83858.0 in Q4 2025.
Azitra (AZTR) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Cash from Investing Activities data on file, last reported at -$37139.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 71.26% year-over-year to -$37139.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198362.0 (up 37.98% YoY) and the FY2025 annual result came in at -$182909.0, up 51.77% from the prior year.
- Cash from Investing Activities improved to -$37139.0 in Q1 2026, from -$83858.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$21686.0 in Q1 2025 to a low of -$115532.0 in Q4 2024.
- A 5-year average of -$70098.7 and a median of -$79304.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 158.87% — and 2025, when it surged 73.25%.
- Tracing AZTR's Cash from Investing Activities over 5 years: stood at -$96791.0 in 2022, then soared by 38.03% to -$59985.0 in 2023, then tumbled by 92.6% to -$115532.0 in 2024, then increased by 27.42% to -$83858.0 in 2025, then soared by 55.71% to -$37139.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$37139.0 (Q1 2026), -$83858.0 (Q4 2025), and -$41078.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -117,541.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117,541.00 |
| Jun 30, 2026 | -117,541.00 |
| Mar 31, 2026 | -37,139.00 |
| Mar 31, 2026 | -37,139.00 |
| Dec 31, 2025 | -83,858.00 |
| Dec 31, 2025 | -83,858.00 |
| Sep 30, 2025 | -41,078.00 |
| Sep 30, 2025 | -41,078.00 |
| Jun 30, 2025 | -36,287.00 |
| Jun 30, 2025 | -36,287.00 |
| Mar 31, 2025 | -21,686.00 |
| Mar 31, 2025 | -21,686.00 |
| Dec 31, 2024 | -115,532.00 |
| Dec 31, 2024 | -115,532.00 |
| Sep 30, 2024 | -107,888.00 |
| Sep 30, 2024 | -107,888.00 |
| Jun 30, 2024 | -74,748.00 |
| Jun 30, 2024 | -74,748.00 |
| Mar 31, 2024 | -81,078.00 |
| Mar 31, 2024 | -81,078.00 |